RESUMO
Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. Dopamine deficit is the cornerstone of its clinical manifestations. Levodopa, the main treatment for this condition, was first used for PD more than 40 years ago and today it still is the most powerful treatment for this disease. In recent years many advances have been made for understanding of the neurochemical mechanisms of this drug. Furthermore, new insights about the genesis of motor complications secondary to its use are known, specially related with the mode of its administration. This article updates the pharmacology of levodopa and its implications for the pathophysiology and treatment of PD. The new available presentations of levodopa are also reviewed. The implications of these advances for the treatment of this disease are commented.
Assuntos
Humanos , Antiparkinsonianos/uso terapêutico , Dopaminérgicos/uso terapêutico , Levodopa/uso terapêutico , Doença de Parkinson/tratamento farmacológico , Antiparkinsonianos/efeitos adversos , Antiparkinsonianos/farmacocinética , Chile , Dopaminérgicos/efeitos adversos , Dopaminérgicos/farmacocinética , Discinesia Induzida por Medicamentos/etiologia , Levodopa/efeitos adversos , Levodopa/farmacocinética , Doença de Parkinson/metabolismo , Doença de Parkinson/fisiopatologiaRESUMO
BACKGROUND: There are doubts wether generic medications have the same bioavailability and efficacy compared with the original drugs developed by pharmaceutical companies with research capabilities. AIM: To compare the pharmacokinetics and clinical (motor) responses of Sinemet and Grifoparkin (generic carbidopa/levodopa 250/25 mg) in patients with advanced Parkinson's disease. PATIENTS AND METHODS: Patients were randomly assigned to Sinemet (15 patients 62 +/- 12 years old; mean disease duration 11 +/- 7 years) or Grifoparkin (15 patients, 64 +/- 11 years old; mean disease duration 12 +/- 4 years) groups. Medication and food were withheld 12 h before the study. Fifteen blood samples were collected (starting 9 AM) immediately before (sample 1, t = 0 min) and after (samples 2-15, t = 20-360 min) oral administration of a single dose of Sinemet or Grifoparkin, and plasmatic L-DOPA was quantified using HPLC with electrochemical detection. Additionally, each patient was clinically evaluated every 20 minutes, using the tapping test and the unified Parkinson's disease scale Hoehn & Yarh. RESULTS: Tmax (time at which the maximal L-DOPA concentration was reached) were 69 +/- 12 min and 64 +/- 11 min for Sinemet and Grifoparkin respectively (NS). Cmax (maximal L-DOPA concentration reached) was 3161 +/- 345 ng/ml for Sinemet and 3274 +/- 520 ng/ml for Grifoparkin (NS). The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS). UPDRS-III value for the best on state and for the worst off state were 23 +/- 11 and 50 +/- 19 for Sinemet and 20 +/- 7 and 46 +/- 13 for Grifoparkin respectively (NS). CONCLUSION: The results obtained showed that both drugs are bioequivalent in patients with advanced Parkinson's disease.
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Antiparkinsonianos/farmacocinética , Carbidopa/farmacocinética , Doença de Parkinson/metabolismo , Levodopa/farmacocinética , Antiparkinsonianos/administração & dosagem , Carbidopa/administração & dosagem , Combinação de Medicamentos , Disponibilidade Biológica , Doença de Parkinson/tratamento farmacológico , Levodopa/administração & dosagem , Método Duplo-CegoRESUMO
Apresentamos breve revisão da literatura sobre os agonistas dopaminérgicos. Referimos os cinco receptores conhecidos e onde estão localizados, as vantagens e as desvantagens de sua utilização nos pacientes com a doença de Parkinson. Introduzidos com o objetivo principal de controlar as limitações da levodopa, aumentando a janela terapêutica, analisamos a farmacocinética, a eficácia e os efeitos colateria da cabergolina, do ropinirole e do pramipexole.